fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ASCO: Neoadjuvant therapy shows superiority for resectable stage III melanoma

Written by | 27 Jun 2024

ASCO: In resectable stage III melanoma, treatment with the immunotherapies ipilimumab and nivolumab before lymph nodes are surgically removed is more effective than treatment with nivolumab after the… read more.

Elahere (mirvetuximab soravtansine) meets primary end point of PICCOLO trial in FR alpha-High, platinum-sensitive ovarian cancer – AbbVie

Written by | 18 Jun 2024

AbbVie announced positive topline results from the Phase II PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRalpha) positive, platinum-sensitive ovarian… read more.

Promising role of antidiabetic drug in cancer control

Written by | 15 Jun 2024

Flinders University researchers have analysed how an antidiabetic treatment could help control the growth of tumours, potentially paving the way for the design of better cancer treatments. The… read more.

Lorbrena (lorlatinib) CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression – Pfizer

Written by | 15 Jun 2024

Pfizer Inc. announced longer-term follow-up results from the Phase III CROWN trial evaluating Lorbrena (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name Lorviqua) versus… read more.

FDA grants accelerated approval to selpercatinib for pediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumors – Eli Lilly

Written by | 14 Jun 2024

The FDA has granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with the following: i. advanced or… read more.

Study: Access to targeted lung cancer drug is cost-prohibitive globally

Written by | 5 Jun 2024

Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health… read more.

Breyanzi (lisocabtagene maraleucel) approved by the FDA for relapsed or refractory follicular lymphoma – BMS

Written by | 28 May 2024

Bristol Myers Squibb announced the FDA has granted accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of… read more.

Integration of pharmacies with physician practices has little impact on cancer drug expenditures

Written by | 26 May 2024

Integration of pharmacies with physician practices, where on-site pharmacies open at physician practice locations, is a growing trend in cancer treatment. However, little is known about how this… read more.

FDA approves Imdelltra (taralatamab-dlle),the first and only T cell engager therapy to treatextensive stage small cell lung cancer – Amgen

Written by | 24 May 2024

Amgen announced that the FDA has approved Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after… read more.

Metformin appears to reduce the risk of blood cancer

Written by | 23 May 2024

Patients who are treated with metformin for type 2 diabetes are less likely to develop a myeloproliferative neoplasm (MPN). Myeloproliferative neoplasms are cancers that occur when the body… read more.

End-of-life systemic treatment for patients with advanced cancers does not improve survival

Written by | 22 May 2024

Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to a study published today in JAMA Oncology by researchers at The University… read more.

Phase III CheckMate-73L trial did not meet its primary endpoint in stage III non-small cell lung cancer – BMS

Written by | 17 May 2024

Bristol Myers Squibb announced the Phase III CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.